Observing hospitalized adults with COVID-19 lung infection
Part of Infections clinical trials.
This study follows adults who are hospitalized with COVID-19 in the lungs. The goal is to better understand how COVID-19 behaves in the hospital over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed COVID-19 infection test
- You were diagnosed with lung infection from COVID-19 (by symptoms, scan, or both)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from adults who are in the hospital for confirmed COVID-19. The goal is to better understand what happens during acute (early) COVID-19 and improve care.
This trial collects and studies COVID-19 test results and other patient information to better predict treatment response and outcomes. Your sample(s) help researchers understand who may improve, worsen, or need different care.
This study follows adults who are in the hospital (including the emergency ward) with a confirmed COVID-19 infection. It aims to learn how COVID-19 affects people in the hospital and how different cases may differ over time.
This study looks at how COVID-19 can affect health and quality of life over the long term. It may help researchers understand symptoms that can last and what changes people experience after recovery.
This study follows adults who had COVID-19 to learn how the illness can affect health over the long term. It may help researchers understand lasting symptoms and who is at higher risk, which could improve future care.
This study looks closely at how your immune system responds during COVID-19. It may help researchers better understand why COVID-19 varies from person to person and how to improve future care.
Hear when a new Sars-CoV2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.